{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["4(5)"],"submitter":["Tarantelli C"],"pubmed_abstract":["Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor with preferred activity toward PI3Kα and PI3Kδ. Despite the clear overall clinical benefit, the number of patients achieving complete remissions with the single agent is relatively low, a problem shared by the vast majority of targeted agents. Here, we searched for novel copanlisib-based combinations. Copanlisib was tested as a single agent, in combination with an additional 17 drugs in 26 cell lines derived from mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and T-cell lymphomas. In vivo experiments, transcriptome analyses, and immunoblotting experiments were also performed. Copanlisib as a single agent showed in vitro dose-dependent antitumor activity in the vast majority of the models. Combination screenin"],"journal":["Blood advances"],"pagination":["819-829"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7065481"],"repository":["biostudies-literature"],"pubmed_title":["Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models."],"pmcid":["PMC7065481"],"pubmed_authors":["Sturz A","Kwee I","Rossi D","Cascione L","Spriano F","Scalise L","Liu N","Arribas AJ","Bertoni F","Politz O","Sperl C","Gritti G","Stathis A","Tarantelli C","Margheriti F","Zucca E","Rinaldi A","Jourdan T","Lange M","Gaudio E","Berthold M"],"additional_accession":[]},"is_claimable":false,"name":"Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models.","description":"Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor with preferred activity toward PI3Kα and PI3Kδ. Despite the clear overall clinical benefit, the number of patients achieving complete remissions with the single agent is relatively low, a problem shared by the vast majority of targeted agents. Here, we searched for novel copanlisib-based combinations. Copanlisib was tested as a single agent, in combination with an additional 17 drugs in 26 cell lines derived from mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and T-cell lymphomas. In vivo experiments, transcriptome analyses, and immunoblotting experiments were also performed. Copanlisib as a single agent showed in vitro dose-dependent antitumor activity in the vast majority of the models. Combination screenin","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Mar","modification":"2026-04-30T22:15:24.516Z","creation":"2025-04-06T01:56:54.457Z"},"accession":"S-EPMC7065481","cross_references":{"pubmed":["32126142"],"doi":["10.1182/bloodadvances.2019000844"]}}